Business Update & Financial Outlook

Hospital: Strong demand across key products bridion (sugammadex) 100 mg/mL Injection • BRIDION sales of $502M increased 19% primarily due to greater share among neuromuscular blockade reversal agents in the U.S. PREVYMIS sales grew 42% driven by continued strong global demand Growth rates exclude the impact of foreign exchange. $502M $426M $387M +67% +19% +15% 2Q21 2Q22 2Q23 $93M +41% PREVYMIS (letermovir) 240 mg, 480 mg tablets Injection 20 mg/mL $103M +18% $143M +42% 2Q21 2Q22 2Q23 MERCK 14

View entire presentation